ANTI-TNF ALPHA PRODUCING LACTIC ACID BACTERIA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

EPO Patent Application EP 3181/141 A1
Application Date: Jun. 21st, 2017

ABSTRACT

The present invention relates to a novel treatment of chronic enterocolitis. More specifically, the invention relates to the production of a medicament comprising anti-TNFalpha antibody producing lactic acid bacteria, and...
Assignee(s):
Inventor(s):
Pieter, ROTTIERS
Klaas, VANDENBROUCKE
Application Number:
17154791.2
International Classification:
A61K 35/74 (20150101); A61K 35/744 (20150101); A61K 36/06 (20060101); A61K 36/064 (20060101); C12N 1/16 (20060101); C12N 1/12 (20060101); A61P 1/00 (20060101); C07K 16/24 (20060101); C12N 15/74 (20060101); C12N 15/81 (20060101)
No Pictures Available

CLAIMS

What is claimed is:

A pharmaceutical composition for oral administration comprising at least one anti-TNFα VHH producing lactic acid bacterium.

DESCRIPTION

The present invention relates to a novel treatment of chronic enterocolitis. More specifically, the invention relates to the production of a medicament comprising anti-TNF producing lactic acid bacteria, and the use of this medicament in the treatment of chronic enterocolitis.
Back to Top